Lesion count

PreclinicalSmall molecule

PPeplin

Lesion count is one of 13 small molecule programs targeting Actinic Keratosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Actinic KeratosisActive, not recruiting

Actinic KeratosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Actinic Keratosis

#DrugCompanyPhaseTrials

Voltaren

Novartis

Approved

2 2

Aldara

BBausch Health Americas, Inc.

Approved

6 3

Taxol

Teva

Approved

—4

Celebrex

PPhiladelphia Eye Associates

Adrucil

Retin-a

VValeant Pharmaceuticals

Klisyri

3 8

Treatment

GSK

Phase 3

1 9

HPV Vaccine

SShanghai Zerun Biotechnology Co.,Ltd

Phase 2

1 10

HW211026

HHubei Bio-Pharmaceutical Industrial Technological Institute Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

TED2 trials

A Long Term Follow up Study of Patients Who Have Completed the PEP005-020 Study

Completed·PPeplin··NCT00952783·98 enrolled

A Long Term Follow up Study of Patients Who Have Completed the PEP005-016 or PEP005-025 Studies

Completed·PPeplin··NCT00953732·117 enrolled

Actinic Keratosis1 trial

A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study

Completed·PPeplin··NCT00989313·43 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Lesion count. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lesion count compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lesion count. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peplin company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: PPeplin

Lesion count

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

TED2 trials

Actinic Keratosis1 trial

References

Drug Info

Quick Facts

Related News